{"filing":{"accession_number":"0001493152-26-031379","cik":"0000315545","ticker":"PVCT","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315226031379/form8-k.htm"},"events":[{"id":15194,"run_id":13561,"accession_number":"0001493152-26-031379","anchor_item_number":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The Board approved conversion of accrued but unpaid directors' fees totaling $542,500 into Series D-1 Preferred Stock (189,554 shares, convertible to 1,895,540 common shares) at $2.862 per share. This is a compensatory arrangement for directors involving equity issuance in satisfaction of outstanding cash compensation obligations, fitting the exec_compensation category under Item 5.02(e). The materiality is high given the substantial dollar amount and dilutive equity impact.","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":12872,"accession_number":"0001493152-26-031379","item_number":null,"item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Board approved conversion of accrued but unpaid directors' fees totaling $542,500 into Series D-1 Preferred Stock (189,554 shares, convertible to 1,895,540 common shares) at $2.862 per share. This is a compensatory arrangement for directors involving equity issuance in satisfaction of outstanding cash compensation obligations, fitting the exec_compensation category under Item 5.02(e). The materiality is high given the substantial dollar amount and dilutive equity impact.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:22:07.066262+00:00","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","filing_date":"2026-06-30"}]}